CN112839962A - 用于治疗癌症的抗mertk抗体 - Google Patents

用于治疗癌症的抗mertk抗体 Download PDF

Info

Publication number
CN112839962A
CN112839962A CN201980067679.7A CN201980067679A CN112839962A CN 112839962 A CN112839962 A CN 112839962A CN 201980067679 A CN201980067679 A CN 201980067679A CN 112839962 A CN112839962 A CN 112839962A
Authority
CN
China
Prior art keywords
seq
amino acids
linked amino
sequence shown
mertk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980067679.7A
Other languages
English (en)
Chinese (zh)
Inventor
T·E·小斯皮尔斯
M·奎格利
V·拉方特
G·C·拉凯斯特拉
L·梁
K·A·奥古斯丁-劳赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN112839962A publication Critical patent/CN112839962A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980067679.7A 2018-10-09 2019-10-08 用于治疗癌症的抗mertk抗体 Pending CN112839962A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862743507P 2018-10-09 2018-10-09
US62/743,507 2018-10-09
PCT/US2019/055155 WO2020076799A1 (en) 2018-10-09 2019-10-08 Anti-mertk antibodies for treating cancer

Publications (1)

Publication Number Publication Date
CN112839962A true CN112839962A (zh) 2021-05-25

Family

ID=68345048

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980067679.7A Pending CN112839962A (zh) 2018-10-09 2019-10-08 用于治疗癌症的抗mertk抗体

Country Status (6)

Country Link
US (1) US20210395392A1 (enExample)
EP (1) EP3864046A1 (enExample)
JP (1) JP2022512642A (enExample)
KR (1) KR20210072059A (enExample)
CN (1) CN112839962A (enExample)
WO (1) WO2020076799A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114591431A (zh) * 2022-05-11 2022-06-07 迈威(上海)生物科技股份有限公司 抗人gas6抗体或其抗原结合片段及其应用
CN119654342A (zh) * 2022-07-28 2025-03-18 乐普创一生物科技（上海）有限公司 抗MerTK抗体及其用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114364703A (zh) * 2019-04-19 2022-04-15 豪夫迈·罗氏有限公司 抗mertk抗体及它们的使用方法
EP4072680A1 (en) * 2019-12-13 2022-10-19 Alector LLC Anti-mertk antibodies and methods of use thereof
EP4126937A1 (en) * 2020-03-31 2023-02-08 Alector LLC Anti-mertk antibodies and methods of use thereof
MX2023008744A (es) 2021-01-29 2023-10-02 Illimis Therapeutics Inc Molecula de fusion que tiene actividad no inflamatoria inductora de la fagocitosis.
EP4355786A1 (en) 2021-06-16 2024-04-24 Alector LLC Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
EP4355783A1 (en) 2021-06-16 2024-04-24 Alector LLC Monovalent anti-mertk antibodies and methods of use thereof
CA3233968A1 (en) * 2021-10-15 2023-04-20 Chiome Bioscience, Inc. Antibody or fragment thereof binding specifically to mertk, and anti-tumor agent

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180002444A1 (en) * 2014-12-22 2018-01-04 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2360254A1 (en) 1999-08-23 2011-08-24 Dana-Farber Cancer Institute, Inc. Assays for screening anti-pd-1 antibodies and uses thereof
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
SG177008A1 (en) 2003-03-05 2012-01-30 Halozyme Inc Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
RS54271B1 (sr) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
NZ582150A (en) 2007-06-18 2012-08-31 Msd Oss Bv Antibodies to human programmed death receptor pd-1
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
US20120230991A1 (en) * 2008-07-29 2012-09-13 Douglas Kim Graham Methods and compounds for enhancing anti-cancer therapy
HRP20170908T1 (hr) 2008-12-09 2017-09-22 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
RS61033B1 (sr) 2011-11-28 2020-12-31 Merck Patent Gmbh Antitela na pd-l1 i njihova upotreba
CA2873402C (en) 2012-05-15 2023-10-24 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
KR102410078B1 (ko) 2012-05-31 2022-06-22 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
PL2925350T3 (pl) 2012-12-03 2019-07-31 Bristol-Myers Squibb Company Zwiększenie aktywności przeciwnowotworowej immunomodulacyjnych białek fuzyjnych fc
HRP20210122T1 (hr) 2013-05-02 2021-04-16 Anaptysbio, Inc. Protutijela usmjerena protiv programirane smrti-1 (pd-1)
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
SG11201601844TA (en) 2013-09-13 2016-04-28 Beigene Ltd Anti-pd1 antibodies and their use as therapeutics and diagnostics
SG11201604738TA (en) 2013-12-12 2016-07-28 Shanghai Hengrui Pharm Co Ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CA2971734C (en) 2014-12-22 2025-11-18 Enumeral Biomedical Holdings Inc Anti-pd-1 antibodies
CA2978942A1 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
EP3307777A4 (en) 2015-06-11 2019-02-13 Wuxi Biologics (Shanghai) Co. Ltd. NOVEL ANTI-PD-L1 ANTIBODIES
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017024515A1 (en) 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
UA124379C2 (uk) 2015-08-11 2021-09-08 Усі Байолоджікс Айрленд Лімітед Нові антитіла проти білка pd-1
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
SG11201804839WA (en) 2015-12-14 2018-07-30 Macrogenics Inc Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
CA3008287A1 (en) 2016-01-11 2017-07-20 Armo Biosciences, Inc. Interleukin-10 in production of antigen-specific cd8+ t cells and methods of use of same
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
CA3068672A1 (en) 2017-06-28 2019-01-03 The Rockefeller University Anti-mertk agonistic antibody-drug conjugates and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180002444A1 (en) * 2014-12-22 2018-01-04 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114591431A (zh) * 2022-05-11 2022-06-07 迈威(上海)生物科技股份有限公司 抗人gas6抗体或其抗原结合片段及其应用
CN114591431B (zh) * 2022-05-11 2022-08-12 迈威(上海)生物科技股份有限公司 抗人gas6抗体或其抗原结合片段及其应用
CN119654342A (zh) * 2022-07-28 2025-03-18 乐普创一生物科技（上海）有限公司 抗MerTK抗体及其用途
CN120484126A (zh) * 2022-07-28 2025-08-15 乐普创一生物科技（上海）有限公司 抗MerTK抗体及其用途

Also Published As

Publication number Publication date
WO2020076799A1 (en) 2020-04-16
KR20210072059A (ko) 2021-06-16
US20210395392A1 (en) 2021-12-23
JP2022512642A (ja) 2022-02-07
EP3864046A1 (en) 2021-08-18

Similar Documents

Publication Publication Date Title
CN110869388B (zh) 用于肿瘤特异性细胞消耗的Fc优化的抗CD25
CN112839962A (zh) 用于治疗癌症的抗mertk抗体
RU2733315C2 (ru) Комбинированная терапия для лечения злокачественной опухоли
JP7680208B2 (ja) 抗ｃｄ２７抗体およびその使用
TW201831511A (zh) 能夠結合cd137和腫瘤抗原的雙特異性結合分子及其用途
AU2016298823A1 (en) Combination of PD-1 antagonist with an EGFR inhibitor
KR102608723B1 (ko) 항―ｐｄ－１ 항체 및 그의 용도
KR20200113228A (ko) 항-4-1bb 항체, 이의 항원-결합 단편 및 이의 의학적 용도
ES2967381T3 (es) Anticuerpos biespecíficos contra CEACAM5 y CD47
JP7490923B2 (ja) 免疫療法効果が向上し副作用が軽減した変異抗ｃｔｌａ－４抗体
US20220363754A1 (en) Anti-tigit antibodies and application thereof
KR20200088810A (ko) 항―ｏｘ４０ 항체 및 그의 용도
AU2020363041B2 (en) Antibodies against the poliovirus receptor (PVR) and uses thereof
JP2024097985A (ja) 抗ｇｉｔｒ抗体およびその使用
JP2025525916A (ja) 抗ｃｃｒ８抗体及び使用方法
CN116199778A (zh) 抗4-1bb抗体及其用途
JP2025535503A (ja) 抗ｃｃｒ８抗体及びその使用
JP2025537137A (ja) 抗ｃｃｒ８抗体、化学療法及び免疫療法の組み合わせを使用する抗がん療法
JP2025514847A (ja) Ｆａｓ軸拮抗薬及びＴｒｅｇ細胞枯渇剤拮抗薬を含む癌の治療のための併用療法
WO2022057910A1 (en) Combination therapies targeting c5ar and pd-1/pd-l1 pathways
TW202305005A (zh) 抗ｓｉｇｌｅｃ組合物及其用途
JP2024507124A (ja) Ｃｄ１１２ｒに対する抗体およびその使用
CN114630679A (zh) 抗garp抗体和免疫调节剂的组合
KR20220103105A (ko) 항-tim3 항체와 병용하여 항-ox40 항체를 사용한 암 치료 방법
RU2827445C2 (ru) Антитела к tigit и их применение

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210525